A Study of Acalabrutinib in Combination with Rituximab + (Bendamustine or Venetoclax) in Subjects with MCL

Trial Identifier: ACE-LY-106
Sponsor: AcertaPharma
Collaborator:
AstraZeneca
NCTID:: NCT02717624
Start Date: May 2016
Primary Completion Date: March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Italy Bologna, Italy, 40138
Italy Turin, Italy, 10126
Poland Krakow, Poland, 30-510
Poland Lodz, Poland, 93-510
Poland Olsztyn, Poland, 10-228
Poland Warszawa, Poland, 02-106
United States of America,  OH Columbus,  OH, United States of America, 43210
United States of America, CA Downey, CA, United States of America, 90241
United States of America, IL Chicago, IL, United States of America, 60612
United States of America, IL Skokie, IL, United States of America, 60077
United States of America, KY Louisville, KY, United States of America, 40207
United States of America, MI Ann Arbor, MI, United States of America, 48109
United States of America, New York Lake Success, New York, United States of America, 11042
United States of America, NJ Hackensack, NJ, United States of America, 07601
United States of America, NJ Morristown, NJ, United States of America, 07960
United States of America, TN Nashville, TN, United States of America, 37203
United States of America, TX Houston, TX, United States of America, 77030
United States of America, WA Seattle, WA, United States of America, 98122
United States of America, WA Seattle, WA, United States of America, 98109